Ingenuity Expands Scope of Licensing Agreement with Daiichi

Ingenuity Systems has announced that they have expanded the terms of their existing agreement with Daiichi Pharmaceutical Co., Ltd. for access to the Ingenuity Pathways Analysis software.

Ingenuity Pathways Analysis (IPA) is a software application that is designed to enable researchers to model, analyze and understand the complex biological systems at the core of life science research.

IPA is deployed in most major pharmaceutical companies and hundreds of biotechnology companies and academic institutions globally.

It supports analysis of all high throughput analysis platforms and is used in virtually all areas of drug discovery and development from target identification and validation to biomarkers, predictive toxicology, and pharmacogenomics.

"Daiichi is one of the first Japanese Pharmaceutical companies to fully expand usage to a corporate wide license and we are very pleased that Daiichi has decided to broadly deploy IPA across its discovery and development sites," stated Peter DiLaura, Vice President, Sales and Customer Support.

"The Ingenuity product line enables IPA users to understand complex biology within their research, in addition to supporting the Bioinformatics team to further develop robust and proprietary computational solutions."

Ingenuity Pathways Analysis is available as a web-delivered, hosted, or deployed solution. Fully functional complimentary trials are available online.